Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy
نویسندگان
چکیده
منابع مشابه
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.
Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease. Autopsy series reveal...
متن کاملPancreatic Cancer: Progress in Systemic Therapy.
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the Western world. Due to lack of specific symptoms and no accessible precursor lesions, primary diagnosis is commonly delayed, resulting in the identification of only 15-20% of patients with potentially curable disease. The major limiting factor is an already locally advanced or metastatic disease...
متن کاملSystemic treatment for inoperable pancreatic adenocarcinoma: review and update
There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and vascular endothelial growth factor receptors...
متن کاملSingapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
INTRODUCTION The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore. MATERIALS AND METHODS The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS Five internatio...
متن کاملPancreatic adenocarcinoma in a patient with relapsed Hodgkin’s lymphoma
After curative treatment of Hodgkin’s lymphoma, increased risk of certain solid tumors has been reported. To best of our knowledge this is the first report of metachronous pancreatic adenocarcinoma which developed outside the previous radiation field in a patient with relapse Hodgkin’s lymphoma. Herein we present an 81-year-old female who developed pancreatic adenocarcinoma four yea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI Journal of the National Cancer Institute
سال: 2014
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/dju011